Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075113 · ClinicalTrials.gov registry record · Phase 1
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01075113 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 16 participants.
The verdict
NCT01075113, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of vorinostat when given together with sorafenib tosylate in treating patients with advanced liver cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Interventions
- DRUG vorinostat
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-08-10 |
| Est. Completion | 2019-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01075113
The ClinicalTrials.gov registry entry for NCT01075113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vorinostat is the first listed.
NCT01075113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01075113 about?
NCT01075113 is a clinical study titled "Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer". This phase I trial is studying the side effects and best dose of vorinostat when given together with sorafenib tosylate in treating patients with advanced liver cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by b...
What is the current status of trial NCT01075113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-08-10. Estimated completion is 2019-07-18.
What interventions are being tested in trial NCT01075113?
The interventions under investigation include: vorinostat (DRUG), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT01075113?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.